University Court of the University of Dundee Patent applications |
Patent application number | Title | Published |
20160000908 | Siglec-9 Binding Agents - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 01-07-2016 |
20130302317 | Siglec-9 Binding Agents - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 11-14-2013 |
20120309087 | CANCER THERAPY - The present invention relates to an improved assay for identifying compounds that may be of use in conjunction with cancer chemotherapeutic agents and anti-proliferative agents, to improve efficacy of such agents and/or render effective compounds with relatively little therapeutic activity. There is also provided a class of compounds identified by said assay which may be used in a combination therapy, with current and novel agents, to treat cancers and other diseases associated with abnormal host cell proliferation, such as psoriasis. | 12-06-2012 |
20120190639 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer. | 07-26-2012 |
20120149778 | COMPOUNDS - The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar′ are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases. | 06-14-2012 |
20120082684 | DIAGNOSIS AND TREATMENT OF CELL PROLIFERATION AND DIFFERENTIATION DISORDERS BASED ON THE FMN2 GENE - The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders. | 04-05-2012 |
20110104149 | SingleC-9 Binding Agents - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 05-05-2011 |
20110021529 | P53 ACTIVATING COMPOUNDS - The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions (involving sirtuin function). | 01-27-2011 |
20100210578 | Prevention/Treatment of Ichthyosis Vulgaris, Atopy and Other Disorders - The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant allele of the filaggrin gene. | 08-19-2010 |
20100017896 | Filaggrin - The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy). | 01-21-2010 |
20090215798 | Inhibitor Compounds - The present invention relates to compounds and uses of compounds which interact with chitinase enzymes, in particular inhibition of those enzymes. | 08-27-2009 |
20090036464 | Treatment Of Posterior Capsule Opacification - This invention relates to a method of testing agents, such as sigma ligands for their potential use in treating posterior capsule opacification (PCO). The present invention also relates to the use of sigma ligands, such as sigma-1 antagonists in the manufacture of a medicament for preventing posterior capsule opacification (PCO), as well as methods of treating PCO using sigma ligands. | 02-05-2009 |
20090010888 | Use of cytochrome P450 reductase as insecticidal target - The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes. | 01-08-2009 |